Press Release: Theriva(TM) Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results

Dow Jones11-12

-- VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 --

-- Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. in October, 2026 for $350,000 upfront and up to $91 million in aggregate milestones as well as royalties --

-- Detailed analyses of data from the VIRAGE Phase 2b clinical trial published in Nature Medicine --

-- Cash and cash equivalents of $8.5 million as of September 30, 2026; cash runway into Q1 2027 --

ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Theriva(TM) Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

"We are pleased with the clinical progress achieved this quarter," said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. "Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year. The VIRAGE2 trial is a crucial step in the clinical advancement of VCN-01 as we evaluate a dosing regimen that is intended to maximize its potential clinical benefit in different cancer therapy combinations. The publication of detailed analyses of the results from the VIRAGE study in Nature Medicine was a gratifying validation of VCN-01's novel mode of action and therapeutic potential in metastatic pancreatic ductal adenocarcinoma (PDAC). The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01. In parallel, we continue to evaluate strategic alternatives intended to maximize value for our stockholders."

Recent Highlights and Anticipated Milestones

VCN-01

Metastatic PDAC:

   -- Two thirds of the target number of patients (4) have been dosed and 
      enrollment is ongoing in the VIRAGE2 Phase 2a clinical trial evaluating 
      the feasibility of more frequent repeated dosing of VCN-01 in combination 
      with standard-of-care chemotherapy in first-line metastatic PDAC patients 
      (EUCT: 2026-525566-21-00; NCT07701486). 
          -- The VIRAGE2 trial builds on feedback from the U.S. Food and Drug 
             Administration (FDA) and European Medicines Agency (EMA) 
             recognizing improved survival outcomes in the VIRAGE2 trial in 
             metastatic PDAC patients receiving 2 doses of VCN-01 administered 
             3-months apart. 
 
          -- The VIRAGE2 trial is designed to evaluate the safety and 
             feasibility of administering at least 3 doses of VCN-01 given 
             approximately 2 months apart in combination with standard-of-care 
             chemotherapy. The trial is expected to enroll 6 evaluable 
             patients. 
 
          -- VIRAGE2 is expected to complete enrollment in Q4 2026, with 
             initial pharmacodynamic and safety/tolerability data anticipated 
             by Q3 2027. 
 
          -- Results from the VIRAGE2 study, if successful, are expected to 
             inform the VCN-01 dosing regimen for future clinical trials 
             evaluating VCN-01 in different cancer therapy combinations, 
             including a potential pivotal Phase 3 clinical trial in metastatic 
             PDAC. 
 
   -- The detailed analyses of results from the VIRAGE Phase 2b trial 
      evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel 
      standard-of-care chemotherapy in metastatic PDAC were recently published 
      in Nature Medicine. The article is entitled "Intravenous 
      hyaluronidase-expressing oncolytic adenovirus with chemotherapy in 
      metastatic pancreatic cancer: a randomised phase 2b trial" and can be 
      read here. 
 
          -- The published analyses of data from the VIRAGE trial highlighted 
             that repeated dosing of VCN-01 in combination with 
             gemcitabine/nab-paclitaxel chemotherapy was well-tolerated, with 
             improved overall survival, progression-free survival and duration 
             of response compared with chemotherapy alone. 
 
          -- Improved survival outcomes were observed in patients treated with 
             two doses of VCN-01 (given 3 months apart) without increased 
             toxicity, providing the rationale for evaluating more frequent 
             administration of additional VCN-01 doses in the VIRAGE2 trial. 
 
          -- Data from the published analyses are consistent with the 
             immune-mediated mechanism of action for VCN-01 that may enhance 
             the anti-tumor effects of a range of coadministered pancreatic 
             cancer therapies. 

Retinoblastoma:

   -- Discussions with key opinion leaders and the FDA are on-going regarding 
      the design of a proposed Phase 2/3 clinical trial of intravitreal VCN-01 
      in combination with intravitreal topotecan in children with 
      retinoblastoma with vitreous seeds that are refractory/resistant to the 
      use of current intravitreal chemotherapy. 
 
          -- The proposed protocol builds on compelling Phase 1 clinical data 
             in this ultra rare pediatric population for which there is no 
             current treatment. 
 
          -- A Type C meeting completed with the FDA on August 31, 2026, 
             provided guidance on the FDA's current expectations for a clinical 
             trial in this patient population, including proposed endpoints and 
             statistical considerations. The FDA encouraged further discussion 
             of the trial design with them, and additional interactions with 
             the FDA are anticipated in Q1 2027. 
 
          -- VCN-01 has Orphan Drug Designation from the FDA, Orphan Medicinal 
             Product Designation from the EMA and Rare Pediatric Disease 
             Designation from the FDA for the treatment of retinoblastoma; if a 
             Biologics License Application (BLA) for VCN-01 for the treatment 
             of retinoblastoma is approved by the FDA by September 30, 2029, 
             the Company may be eligible to receive a Priority Review Voucher. 

SYN-004

   -- Theriva completed the sale of Theriva's portfolio of antibiotic-degrading 
      enzymes, including SYN-004 (ribaxamase), SYN-007 (reformulated 
      ribaxamase), and SYN-006 (carbapenemase), pursuant to an asset sale 
      agreement with Biossil Labs Inc. ("Biossil"). 
 
          -- Biossil acquired all rights, title and interest in SYN-004, 
             SYN-007 and SYN-006, and assumed all responsibility and costs for 
             development and commercialization of the assets. 
 
          -- Under the terms of the agreement, the Company received a $350,000 
             upfront payment upon closing and is eligible for an aggregate of 
             up to $3 million in regulatory milestones and up to $88 million in 
             sales milestones, as well as single-digit royalties on net product 
             sales (capped at $250 million). 
 
          -- Concurrent with the Biossil asset sale, Theriva amended its Asset 
             Purchase Agreement with PREV ABR LLC (from 2012) under which the 
             Company originally acquired SYN-004 (ribaxamase) and the related 
             product portfolio. Per the terms of the amendment, Theriva paid 
             PREV ABR $140,000 upon receipt of the $350,000, and will be 
             required to pay PREV 50% of future regulatory and sales milestone 
             payments, 331/3% of royalty payments received by Theriva, and 50% 
             of other consideration received by Theriva in relation to the 
             transferred assets, up to an aggregated total of $13 million. 

Third Quarter Ended September 30, 2026 Financial Results

General and Administrative Expenses

General and administrative expenses decreased to $923,000 for the three months ended September 30, 2026, from $1.9 million for the three months ended September 30, 2025. This decrease of 51% primarily reflects a $841,000 decrease in the fair value of contingent consideration recognized in the three months ended September 30, 2026, compared to a $633,000 increase recognized in the same period in 2025, partially offset by a current year increase in legal fees. The charge related to stock-based compensation expense was $119,000 for the three months ended September 30, 2026, compared to $118,000 for the three months ended September 30, 2025.

Research and Development Expenses

Research and development expenses decreased to $612,000 for the three months ended September 30, 2026, from approximately $2.6 million for the three months ended September 30, 2025. This decrease of 76% is primarily the result of lower direct expenses related to the completion of the VCN-01 Phase 2b PDAC clinical trial, lower direct expenses related to VCN-01 manufacturing activities, lower direct clinical trial expenses related to the paused Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients, lower expenses related to SYN-020, partially offset by expenses associated with the conduct of the VIRAGE2 Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period.

Other Income/Expense

Other income was $64,000 for the three months ended September 30, 2026, compared to other income of $79,000 for the three months ended September 30, 2025. Other income for the three months ended September 30, 2026 is comprised of interest income of $64,000. Other income for the three months ended September 30, 2025 is primarily comprised of interest income of $65,000 and an exchange gain of $14,000.

Cash and Cash Equivalents

Cash and cash equivalents totaled $8.5 million as of September 30, 2026, a decrease of $4.6 million from December 31, 2025. During the year ended December 31, 2025, and nine months ended September 30, 2026, the primary use of cash was for working capital requirements and operating activities, which resulted in a net loss of $23.7 million and $6.7 million for the year ended December 31, 2025, and the nine months ended September 30, 2026, respectively.

About Theriva(TM) Biologics, Inc.

Theriva(TM) Biologics (NYSE American: TOVX) is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company's subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and intratumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead clinical-stage candidate is VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. For more information, please visit Theriva(TM) Biologics' website at www.therivabio.com.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may, " "should," "potential," "continue," "expects," "anticipates," "intends, " "plans," "believes," "estimates," and similar expressions, and include statements regarding VIRAGE2 completing enrollment in Q4 2026, with initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027; the VIRAGE2 trial being expected to enroll 6 evaluable patients; the results from the VIRAGE2 trial informing the VCN-01 dosing regimen for future clinical trials evaluating VCN-01 in different cancer therapy combinations, including a potential pivotal Phase 3 clinical trial in metastatic PDAC; the proposed Phase 2/3 clinical trial of intravitreal VCN-01 in combination with intravitreal topotecan in children with retinoblastoma with vitreous seeds that are refractory/resistant to the use of current intravitreal chemotherapy; continuing to evaluate strategic alternatives intended to maximize value for our stockholders; the potential payment from Biossil of up to $91 million in aggregate milestones as well as royalties on net product sales (capped at $250 million); the Company having a cash runway into Q1 2027; publication of detailed analyses of the results from the VIRAGE study in Nature Medicine providing a validation of VCN-01's novel mode of action and therapeutic potential in metastatic pancreatic ductal adenocarcinoma (PDAC); the Company being eligible to receive a Priority Review Voucher if a Biologics License Application (BLA) for VCN-01 for the treatment of retinoblastoma is approved by the FDA by September 30, 2029, and additional discussions of the retinoblastoma clinical development plan with the FDA anticipated in Q1 2027. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to finalize protocols for future clinical trials evaluating VCN-01; results of future trials supporting further clinical development of VCN-01 and supporting the benefits of more frequent repeated dosing of VCN-01; the Company's ability to obtain development funding and/or partnerships; the Company's ability to receive any milestone or royalty payments from Biossil, the Company's commencement of planned clinical trials, which remains subject to sufficient financing; the Company's ability to raise capital and/or enter into one or more strategic alternatives, that may include a business combination, merger or reverse merger; the Company's ability to reach clinical milestones when anticipated, including the ability to continue to enroll patients as planned; generating clinical data that establishes VCN-01 may improve patient outcomes in cancer patients; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, including approval of VCN-01 to treat cancer patients; regulatory limitations relating to the Company's ability to promote or commercialize its product candidates for the specific indications; acceptance of the Company's product candidates in the marketplace; the successful development, marketing or sale of the Company's products; developments by competitors that render such products obsolete or non-competitive; the Company's ability to maintain license agreements; the continued maintenance and growth of the Company's patent estate; the ability to continue to remain well financed; and other factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For further information, please contact:

Investor Relations

Kevin Gardner

LifeSci Advisors, LLC

kgardner@lifesciadvisors.com

 
 
                Theriva Biologics, Inc. and Subsidiaries 
                  Condensed Consolidated Balance Sheets 
            (In thousands except share and par value amounts) 
 
                            September 30, 2026     December 31, 2025 
                           --------------------   ------------------- 
                                 (Unaudited) 
         Assets 
 
Current Assets 
  Cash and cash 
   equivalents              $             8,473    $           13,056 
  Tax credit receivable                   1,673                 3,351 
  Prepaid expenses and 
   other current assets                     475                 1,060 
                               ----------------       --------------- 
     Total Current Assets                10,621                17,467 
 
Non-Current Assets 
Property and equipment, 
 net                                        155                   222 
Restricted cash                              44                    46 
Right of use asset                        1,704                   803 
In-process research and 
 development                             18,956                19,619 
Deposits and other assets                    80                    82 
                               ----------------       --------------- 
Total Assets                $            31,560    $           38,239 
                               ================       =============== 
 
    Liabilities and 
  Stockholders' Equity 
 
Current Liabilities: 
  Accounts payable          $               467    $            1,014 
  Accrued expenses                        6,459                 6,276 
  Accrued employee 
   benefits                                 284                   443 
  Deferred research and 
   development tax 
   credit-current 
   portion                                  995                 1,675 
  Loans payable-current                      34                    57 
  Operating lease 
   liability-current 
   portion                                  540                   549 
                               ----------------       --------------- 
     Total Current 
      Liabilities                         8,779                10,014 
 
Non-current Liabilities 
  Non-current contingent 
   consideration                          8,978                10,004 
  Loan Payable - 
   non-current                            1,627                 1,671 
  Non-current deferred 
   research and 
   development tax 
   credit                                   197                   815 
  Non-current operating 
   lease liability                        1,226                   352 
                               ----------------       --------------- 
  Total Liabilities                      20,807                22,856 
 
Commitments and 
Contingencies (Note 14)                      --                    -- 
Stockholders' Equity: 
  Common stock, $0.001 
   par value; 350,000,000 
   shares authorized, 
   45,921,478 issued and 
   45,892,668 outstanding 
   at September 30, 2026 
   and 35,717,159 issued 
   and 35,688,350 
   outstanding at 
   December 31, 2025                         45                    34 
  Additional paid-in 
   capital                              376,298               373,592 
  Treasury stock at cost, 
   28,810 shares at 
   September 30, 2026 and 
   at December 31, 2025                    (288)                 (288) 
  Accumulated other 
   comprehensive income                     140                   755 
  Accumulated deficit                  (365,442)             (358,710) 
                               ----------------       --------------- 
Total Stockholders' 
 Equity                                  10,753                15,383 
                               ----------------       --------------- 
 
Total Liabilities and 
 Stockholders' Equity       $            31,560    $           38,239 
                               ================       =============== 
 
 
 
Theriva Biologics, Inc. and Subsidiaries 
 Condensed Consolidated Statements of Operations and 
 Comprehensive Loss 
 (In thousands, except share and per share amounts) 
 (Unaudited) 
 
                      For the three months       For the nine months 
                      ended September 30,        ended September 30, 
 
                       2026          2025         2026          2025 
 
License Revenue     $        --   $       --   $       300   $       -- 
 
Operating Costs 
and Expenses: 
  General and 
   administrative           923        1,889         5,025       14,516 
  Research and 
   development              612        2,551         2,234        7,472 
 
     Total 
      Operating 
      Costs and 
      Expenses            1,535        4,440         7,259       21,988 
 
 
Loss from 
 Operations              (1,535)      (4,440)       (6,959)     (21,988) 
 
 
Other 
Income/Expense: 
  Foreign currency 
   exchange gain             --           14             1           30 
  Interest income            64           65           226          215 
 
     Total Other 
      Income                 64           79           227          245 
 
 
Net Loss before 
 income taxes            (1,471)      (4,361)       (6,732)     (21,743) 
Income tax 
benefit                      --           --            --           -- 
 
Net Loss 
 Attributable to 
 Common 
 Stockholders       $    (1,471)  $   (4,361)  $    (6,732)  $  (21,743) 
 
 
Net Loss Per Share 
 - Basic and 
 Dilutive           $     (0.03)  $    (0.45)  $     (0.15)  $    (3.38) 
 
 
  Weighted average 
   number of 
   shares 
   outstanding 
   during the 
   period - Basic 
   and Dilutive      45,892,668    9,676,521    44,303,676    6,429,227 
 
 
Net Loss                 (1,471)      (4,361)       (6,732)     (21,743) 
(Loss) gain on 
 foreign currency 
 translation               (107)         (30)         (615)       1,941 
 
Total 
 comprehensive 
 loss               $    (1,578)  $   (4,391)  $    (7,347)  $  (19,802) 
 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment